Core Viewpoint - The company has successfully passed the consistency evaluation for the generic drug Roxithromycin capsules (150mg) by the National Medical Products Administration of China, which will strengthen its position in the anti-infection sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Roxithromycin capsules, marking it as the first company to pass this evaluation for this dosage form [1] - Roxithromycin is a second-generation macrolide antibiotic known for its good acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] Group 2: Clinical Applications - The drug is clinically applicable for treating infections caused by Roxithromycin-sensitive pathogens in areas such as otolaryngology, respiratory tract, skin and soft tissue, and urogenital infections [1] Group 3: Market Position and Future Prospects - The product is listed as a Class B drug in the National Medical Insurance Directory (2025 version), which may enhance its market accessibility [1] - The approval is expected to help the company consolidate its competitive advantage in the anti-infection field and drive further product development, potentially leading to greater returns for the company and its shareholders [1]
联邦制药(03933)：罗红霉素胶囊通过一致性评价